论文部分内容阅读
During recent years, Atrial Fibrillation (AF) is emerging as a major public health problem among the aging population.The ultra-rapid delayed rectifier potassium current (IKur), encoded by Kv 1.5 gene, is a selective target for the treatment of AF.Therefore, several pharmaceutical companies have made their efforts in developing selective Kvl.5 blockers by taking some deeper insight into action mechanism and structural information.